| Name | Title | Contact Details |
|---|
Also known as Advantagene. Inc., we are a Massachusetts-based biotechnology company developing our proprietary immuno-oncology platforms for the treatment of solid tumors, including our Gene Mediated Cytotoxic (GMCI™) platform and our rQNestin34.5 platform. GMCI™ is an "off-the-shelf" immunotherapy designed to generate a personalized, robust, and precise systemic response from the patient's own immune system against his or her cancer.
CHUL Research Center is a Quebec, QC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
GRAIL`s mission is to detect cancer early, when it can be cured.
Ribon Therapeutics is a biotech company focused on developing first-in-class therapeutics targeting mono(ADP-ribosyl)ating PARPs for cancer.
Quentis is at the forefront of the next generation of immuno-oncology companies that are translating novel biology into new therapeutic approaches to help more patients benefit from immunotherapy.